These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37800793)

  • 41. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States.
    Dieterich DT; Bernstein D; Flamm S; Pockros PJ; Reau N
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1311-1322. PubMed ID: 32813292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
    Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Shimizu T; Watakabe K; Enomoto N; Izumi N
    PLoS One; 2019; 14(2):e0211122. PubMed ID: 30768601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
    Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
    Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China.
    Mei H; Zhou H; Hou M; Sun J; Zhang L; Luo J; Jiang Z; Ye X; Xu Y; Lu J; Wang H; Hui A; Zhou Y; Hu Y
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102158. PubMed ID: 37700877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
    Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis.
    Rose PD; Au M; Woodman RJ; Tee D; Chinnaratha MA
    Dig Liver Dis; 2021 Nov; 53(11):1396-1403. PubMed ID: 34373229
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of Thrombocytopenia in Patients with Chronic Liver Disease.
    Saab S; Brown RS
    Dig Dis Sci; 2019 Oct; 64(10):2757-2768. PubMed ID: 31011942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia.
    Estcourt LJ; Malouf R; Hopewell S; Doree C; Van Veen J
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011980. PubMed ID: 29709077
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
    Estcourt LJ; Stanworth SJ; Doree C; Hopewell S; Trivella M; Murphy MF
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010983. PubMed ID: 26576687
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
    N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure.
    Shirley M; McCafferty EH; Blair HA
    Drugs; 2019 Oct; 79(15):1689-1695. PubMed ID: 31529283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.
    Tsuji Y; Kawaratani H; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Takaya H; Shimozato N; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
    Dig Dis; 2020; 38(4):329-334. PubMed ID: 31655803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
    Maan R; de Knegt RJ; Veldt BJ
    Drugs; 2015 Nov; 75(17):1981-92. PubMed ID: 26501978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis.
    Lindquist I; Olson SR; Li A; Al-Samkari H; Jou JH; McCarty OJT; Shatzel JJ
    Platelets; 2022 Jan; 33(1):66-72. PubMed ID: 33459573
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors.
    Gao Y; Liu Q; Shen Y; Li Y; Shao K; Ye B; Shen Y; Zhou Y; Wu D
    Platelets; 2022 Oct; 33(7):1024-1030. PubMed ID: 35040375
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence.
    Qureshi K; Patel S; Meillier A
    Int J Hepatol; 2016; 2016():1802932. PubMed ID: 27800187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure.
    Saab S; Bernstein D; Hassanein T; Kugelmas M; Kwo P
    J Clin Gastroenterol; 2020 Jul; 54(6):503-511. PubMed ID: 32195771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.